Profound Medical to Present at the 2022 Jefferies London Healthcare Conference
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) announced that CEO Arun Menawat will present a business update at the Jefferies London Healthcare Conference on November 15, 2022, at 12:20 p.m. GMT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) announced that CEO Arun Menawat will present a business update at the Jefferies London Healthcare Conference on November 15, 2022, at 12:20 p.m. GMT. The presentation will be broadcast live and archived on the Company's website under 'Webcasts' in the Investors section.
Profound specializes in customizable, incision-free therapies for the ablation of diseased tissue, including TULSA-PRO® for prostate treatment and Sonalleve® for uterine fibroids and bone metastases.
Details
News Market Reaction – PROF
The recorded move for PROF in the trading session of this news was +1.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company’s business at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:20 p.m. GMT.
The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.